One of the challenges in addressing public transport sexual harassment is the lack of clear and specific definitions of what constitutes unwanted behaviors. While some acts of harassment are overt and easily recognizable, others may be more subtle and difficult to identify. This ambiguity can make it harder for victims to report incidents and for authorities to take appropriate action.Emily's story begins in a rural village in China, where she was born to loving parents. Tragically, at the tender age of 5, Emily was kidnapped while playing near her home. Sold to a human trafficking ring, Emily endured years of exploitation and abuse, passed from one owner to another. Despite the harrowing circumstances, Emily never gave up hope of finding her way back to her family.
Amidst the sea of sorrow and confusion, one thing became abundantly clear - the boy, whose name may never be known, had touched the hearts of many. His untimely passing served as a stark reminder of the fragility of life and the indiscriminate nature of tragedy.In conclusion, the soaring performance of the China Golden Dragon Index, coupled with the bullish sentiment among foreign investors, underscores the attractiveness of Chinese assets in the global investment arena. As China continues to drive innovation, economic reform, and market liberalization, foreign investors have identified the vast opportunities that the Chinese market offers. With sustained momentum and favorable market conditions, China is poised to emerge as a key player in the global investment landscape, attracting capital inflows and driving economic growth in the years to come.
3. Manuel Noriega - Panama
The Times view on Ashtead’s stock market shift: Don’t Tell Sid
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows: Abstract Title : PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial Abstract Number: SESS-2211 Session : Concurrent Poster Spotlight Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations Date/Time : Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT) Conference Call Information Relay Therapeutics will host a conference call to discuss these data on Wednesday, December 11, 2024 at 7:00 a.m. ET (6:00 a.m. CT). Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available following the event. The poster will be available at the start of the session on the company’s website at https://relaytx.com/publications/ . About RLY-2608 RLY-2608 is the lead program in Relay Therapeutics’ efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 300,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine. Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation. For more information on RLY-2608, please visit here . About Relay Therapeutics Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics’ strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics’ portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, including lirafugratinib as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics’ use of capital, expenses and potential cost savings. The words “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics’ drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact: Megan Goulart 617-322-0814 mgoulart@relaytx.com Media : Dan Budwick 1AB 973-271-6085 dan@1abmedia.com
EAST LANSING, Mich. — Rutgers saved its best for last. After getting gutted last week in a last-second loss to Illinois that rattled the foundation of the program, no one would have blamed the Scarlet Knights for mailing in their regular-season finale. Instead, Rutgers responded with a performance that will send it into the postseason feeling like, yet again, the team that should have been counted out a long time ago will be fighting for something special. Extra motivation? Rutgers needed none of it Saturday. The Scarlet Knights spent one day to put rehash what went wrong against Illinois. They said they moved on and proved it early, dismantling Michigan State for a 41-14 win that was never in jeopardy. The bounce-back performance should be something to give coach Greg Schiano’s team something to be proud of with whatever comes next in the postseason. After all: It was Michigan State fighting for a postseason berth Saturday, but Rutgers looked like the playing with its season on the line. Rutgers can sit back and wait for its bowl game destination knowing it salvaged its season after a four-game losing streak and quickly erased what was one of its worst losses ever. On Saturday, te Scarlet Knights were better in every facet. Offensively, defensively, special teams — this was the type of complementary football that has escaped Rutgers until its final game of the regular season. If this was the final time fans see senior running back Kyle Monangai in a Rutgers uniform, the senior gave one last memorable performance. Monangai moved past Terrell Willis for second place on the school’s all-time rushing list. He racked up 101 of his 129 yards in the first half to help Rutgers rattle off 34 unanswered points, spanning the second and third quarters. In a potentially fitting finale, Monangai recorded a 100-yard game for the third straight season against Michigan State. After all, it was here in East Lansing where Monangai first exploded onto the scene in 2022. Just three years ago, Monangai rattled off a then-Big Ten record for Rutgers after carrying 24 times for 162 yards and a touchdown. It was a game Rutgers still found a way to lose. There might not be a better embodiment of Rutgers’ resurgence than Monangai who went from an unheralded recruit to the Big Ten rushing champ to a player who went back to work time and time again. When Rutgers needed one last week of work, it turned to wise words from the face of its senior class, who put it simply ... to move past the heartbreak, Rutgers needed to “just get back to work”. Instead of checking out, Rutgers got back to work. Observations Move to the spread? Experimenting with different packages, formations and tempo, it was somewhat startling that Rutgers not only spread things out — but thrived doing so. Quarterback Athan Kaliakmanis hit sophomore Ian Strong for a 9-yard touchdown pass. At that point, with Rutgers leading 31-7, it was becoming clear that the offense was going to operate at a high level with whatever it was hoping to accomplish. That may be the best news for Rutgers. With Monangai and the run game, the Scarlet Knights were able to bring balance to its offense. Will that be the case next season? Either way, Rutgers will have a quarterback in Kaliakmanis and a loaded core of young receivers who could give the Scarlet Knights a foundation to build around. After throwing for 150 yards Saturday, Kaliakmanis will need 248 yards in the bowl game to reach the 2,700-yard mark, which has only been reached by three other Rutgers passers — Ryan Hart, Mike Teel and Gary Nova — who also have substantial players in program lore. Dariel Djabome delivers all season long From the first game of the regular season to the last, the junior linebacker from Quebec was one of Rutgers’ biggest revelation. The team’s leading tackler, who was thrust into the starting lineup to replace injured captain Mohamed Toure, delivered the game’s biggest play when he stuffed running back Kay’ron Lynch-Adams in the backfield for a turnover on downs. At the time, Michigan State had the chance to tie the game with a field goal but gambled facing 4th-and-1 at Rutgers’ 6-yard line. With Michigan State facing a 10-7 deficit with 10:01 to play in the second quarter, the momentum fully swung in Rutgers’ favor from there as the Scarlet Knights scored on five of its six first-half possessions. Special teams deja vu Michigan State avoided complete destruction from a special teams blunder, but it just goes to show how steady that unit has been under Schiano. Halfway through the first quarter, long snapper Jack Carson Wentz sent a high snap through the hands of punter Ryan Eckley, who was able to scoop it up and stay out of the end zone when he was hit by freshman Ben Black. Rutgers took over at the 1-yard line but went backwards on a illegal motion by Monangai, leading to an eventual 25-yard field goal by Jai Patel that put Rutgers up 10-7 with 7:29 left in the first quarter. Last season, Michigan State punter Michael O’Shaughnessy dropped a snap, opening the door for Rutgers to rally for an 18-point comeback in the fourth quarter of an eventual 27-24 win for the Scarlet Knights. Go big or go home What was more unlikely? Senior Tyler Needham returning from what was previously diagnosed as a season-ending injury or him playing as a tight end? Needham, switching from No. 56 to 86, returned to the field three weeks removed from a knee injury and was used as a sixth offensive lineman, giving the Scarlet Knights a jumbo package look in a game decided in the trenches. Needham started the first nine games at right tackle before injuring his knee against Minnesota three weeks ago. Rutgers diagnosed his injury as season-ending, but the Philadelphia native was back in the starting lineup Saturday, giving the Scarlet Knights another option for its injury-decimated group of tight ends. While redshirt sophomore Mike Higgins saw the field, Rutgers used its jumbo package for a majority of its offensive snaps. Blustery Big Ten weather The official reading at kickoff was 24 degrees. Snow covered the field and fell like confetti from start to finish in a game between two teams trying to take advantage of the weather. Hits felt bigger, catches felt grittier and this Nov. 30, regular-season finale felt like the embodiment of Big Ten football. On a day, where Michigan State was playing for a bowl berth, Rutgers came into Spartan Stadium and was simply better across the board. Bonus coverage - With the win, Rutgers finished the regular season with a 7-5 record and 4-5 mark in Big Ten play. The 7-5 record will stand as Rutgers’ best regular-season record since 2014 when the Scarlet Knights recorded the same overall finish in its inaugural season in the Big Ten. Its four Big Ten wins also set a new program best. - The snow was a no-go, apparently. Michigan State running back Nate Carter was flagged for unsportsmanlike conduct after celebrating by doing snow angels following his first touchdown run of the game. It was a significant penalty, too. On the ensuing kickoff, Jonathan Kim booted the ball out of bounds. With the penalty yardage stacked together, Rutgers started with possession at the 50-yard line for its first drive, which ended with a 7-yard touchdown run by Monangai. Injury updates The Scarlet Knights listed 13 players as pre-game scratches on their availability report . The list included three new seniors — defensive end Aaron Lewis, cornerback Eric Rogers and safety Desmond Igbinosun — who all played last week against Illinois. In addition to those three regulars, Rutgers listed four other major contributors — wide receiver Christian Dremel, offensive lineman Tyler Needham, tight end Mike Higgins and cornerback Al-Shadee Salaam — as questionable two hours before kickoff. All four ended up playing, opening the door for Needham’s intriguing return as a jump-package option. The line Rutgers opened as a one-point favorite Sunday, but the lined eventually moved to favor Michigan State. At the time of kickoff, Michigan State was a favorite by 1 1/2 points, according to multiple sports books. The total points was set at 47 1/2. MORE RUTGERS COVERAGE Rutgers loses physical battle with Texas A&M, leaves Las Vegas with lost opportunities What’s Rutgers’ injury situation vs. Michigan State? Scarlet Knights thin again Rutgers vs. Texas A&M FREE LIVE STREAM (11/30/24) | How to watch men’s college basketball in Las Vegas online Everything Rutgers fans need to know about Michigan State showdown Married to Rutgers: Fans sneak away from Vegas hoops tournament to say, ‘I do’ Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription. Patrick Lanni may be reached at planni@njadvancemedia.com .NoneIn the wake of this tragedy, the insurance industry is left reeling from the loss of one of its most prominent figures. Smith was widely respected for his leadership and vision, and his death has had a profound impact on the company and its employees. As the investigation continues and the legal process unfolds, the industry will be watching closely to see how justice is served in this high-profile case.
Volkswagen’s new electric Golf will get the Rivian treatment
Former President Jimmy Carter dies at age 100Title: Trump Launches "Fight Fight Fight" Perfume: Embodies the Spirit of Victory